Bhagwat's remarks came after Hindu groups filed legal petitions seeking the demolition of mosques they claim were built on temple sites, including Shahi Jama Masjid in UP's Sambhal. In response ...

Dec 23 (Reuters) - Merck (MRK.N), opens new tab will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday.

And that just because he’s calling a halt to all these mandir-masjid issues, it doesn’t mean people are going to stop, because this is a long-awaited quest for justice for all the “awful things done ...

Merck just closed a deal to develop a weight-loss drug. The market appears to think Viking Therapeutics is threatened by that data. There's little reason to write off Viking here. First, let's get ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove ...

RAHWAY, N.J., December 20, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for ...

Merck's DOR/ISL regimen demonstrated non-inferiority to bART and BIC/FTC/TAF in two pivotal Phase 3 trials for adults with HIV-1. Both trials achieved primary safety objectives, with detailed ...

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead Sciences' lenacapivir, Merck & Co.'s islatravir is making further strides as a combination treatment with ...